It's good for the children to see the process. If you want the type of returns I get and give well you had better learn how to create watch lists. That being said most often it boils down to gamblers intuition - Right now I lack an overall theme in my mind for the market. Any stock I buy must have it's own story or investment thesis and ILMN has that in spades. This is a classic you bought the wrong company bub story and they have paid for buying GRAIL dearly.. I've see this happen before once you divest a year or so later you are big./ since the aim of any HIGH ANXIETY stock would be to hold for a good while-- through the anxiety I think and my instinct is the first stock we buy should be ILMN. Because it has a thesis::: (from Ocean Road Capital’s Substack by Ocean Road Capital.)-: Illumina’s acquisition of GRAIL was a major mistake, but divesting GRAIL is a turning point. Illumina can now focus on its main business, which holds about 80% of the next-generation sequencing (NGS) market. Their business model relies on selling instruments and consumables, which brings in steady revenue. Without GRAIL, Illumina can grow its genomics ecosystem, benefiting from high switching costs and a growing user base in research and clinical markets. This shift is expected to boost growth and profitability, making Illumina stock a good long-term investment. The clinical market, especially oncology diagnostics, is a big growth area for Illumina. This market could reach $75 billion by 2035, growing at 27% CAGR annually. Illumina’s sequencing technologies are crucial for this market, used in tumor analysis, cancer screening, and precision oncology. While GRAIL’s cancer detection tests faced challenges, Illumina’s core technologies are still important for cancer monitoring and reproductive testing, which have fewer regulatory issues. With GRAIL gone it has had a positive impact on Illumina's cost structure and margins. Under previous leadership, expenses rose. Illumina is now reducing expenses by $175 million through workforce reductions and cuts in vendor spending and particularly in R&D it is targeting to spend roughly 10% of revenue while maintaining its innovative edge all of these measures could lead to improvements in Gross Margins in 60-70% range and operating margins to 20-30%. This improvement will come from increased efficiency, cost-cutting measures, and better utilization of NovaSeq X instruments. Despite competition from companies like Element Biosciences and Ultima Genomics, Illumina’s established ecosystem and customer loyalty are strong defenses. The NovaSeq X system is competitive in price and functionality, and continuous innovation will help maintain its leadership. Overall Illumina’s outlook has improved after the sell-off of GRAIL. The stock has a potential upside of about 56%, with a fair value estimated at $183 per share, using a 24x 2025 estimated P/E multiple, similar to other life sciences diagnostics tools companies.
Well that's it. I sent the buy in just now to the HF. I have broken into the cash hoarding. Has The Bull Trap just captured me.? ILMN to be bought shortly.
Well I'm off the schnide. I don't know what a schnide is but this is something when you break through a barrier you say in like 1910. I've tipped my toe in the water- tasted the waterfall- planted that first seed. and now I like to reward myself with a sweet treat my wife will freak out about.. in a bad way. Cheese makes her break out but.... Favorite SERVES 12-16
the sequel. This is an old Hollywood trick. When you run out of ideas.. The Sequel.. but we will do it better. The first stock has been bought ILMN>. The good news. HF said ' we have owned it before ' That's always re- assuring. Alright kiddos on PAGE 388 welcome to: GBA PRESENTS- HIGH ANXIETY!!!
Good Morning and welcome to part two of the public games... THE HIGH ANXIETY NEWSLETTER-: -- THE LIST -- (TAKING COHR OUT UP TO MUCH) 1: TWLO 2: THO 3: ONDS 4: COHRXXXXXXXX REPLACE? CHEF? 5: DOCN <------ (1) 6: ILMN <------------ (2) <--- BOUGHT-! 7: DDOG 8: WWW 9: SGHC 10: KYN _________________________ We'll add to this list most recent GBA buys BHVN, LEG & LSPD& maybe SOUN Considering WKSP & BRFH as inclusions. Once we get a bunch of names together I'll whittle them down with some TA./ ////////////////////////////////////////////////////// I'll endeavor to start research into some more of these names. I also want to get a healthy dose of nuclear ideas in here. In terms of themes: we started the AI craze- first there for sure and we stated the Space Stock craze for sure. First again. Amazing gains both sectors but what is next... Looking at Defense stocks, steel stocks, energy stocks and healthcare. ... And nuclear. I don't know how the politics play into this- The Biden team supports... but you can't get more HIGH ANXIETY than having a nuclear plant next door! The U.S. Dept. of Energy (DOE) announced six companies have successfully bid to provide deconversion services for high-assay low-enriched uranium (HALEU) fuel to support advanced nuclear reactors. The DOE on October 8 announced the complete list of successful bidders. They include Nuclear Fuel Services, part of BWX Technologies (BWXT); American Centrifuge Operating, part of Centrus Energy; Framatome; GE Vernova; Orano; and Westinghouse. The DOE contracts are designed to support the buildout of a U.S. supply chain for fuels for advanced nuclear reactors. Many of those reactors will require HALEU fuel to enable smaller designs and support longer operating cycles. ///////////////////////////////////////////////////////// USD Centrus Energy Corp. (LEU) 65.25+0.59(+0.91%) At close: October 8 at 4:00 PM EDT 66.01+0.76(+1.16%) Pre-Market: 7:10 AM EDT